FDAnews
www.fdanews.com/articles/96902-kinemed-and-merck-enter-collaboration-in-atherosclerosis

KineMed and Merck Enter Collaboration in Atherosclerosis

August 7, 2007

KineMed, Inc., a pathway-based drug discovery and development company, announced today a non-exclusive collaboration with Merck & Co., Inc., under which KineMed's proprietary reverse cholesterol transport (RCT) technology will be used to evaluate investigational compounds discovered by Merck.
PR Newswire